IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Snapdragon Chemistry, now part of Cambrex, our chemists specialize in creating custom solutions and technologies to take on your toughest process development and production challenges. This includes expertise in designing and building reactors that enable seamless technology transfer as a process scales up for commercial manufacturing.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
If you’re looking to outsource drug product development to a CDMO, you need a collaborative partner who will engage you deeply to understand the unique needs of your project.
From pre-formulation to commercial manufacturing and packaging, you can trust Cambrex to deliver your complex dosage forms with the perfect combination of technology, expertise, and collaboration.
We are equipped to take on projects at any size or scale, offering established pediatric formulation and development expertise and to-scale manufacturing capabilities.
Biopharma companies at all stages of development, rely on our expertise and broad capabilities to produce the clinical trial supply of drug products they need, when they need them.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex offers a comprehensive suite of testing services for complex biopharmaceuticals including standalone analytical R&D, method validation, release testing, ICH stability, and routine QC testing.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
05.11.2021
Waltham, MA – May 11, 2021 – Snapdragon Chemistry is pleased to announce the appointment of Lisa Reed as Head of Quality Assurance at its Waltham headquarters. Lisa has more than 25 years of experience in quality assurance in the pharmaceutical, biotechnology and drug manufacturing industries and has a track record of proven results in maintaining the highest possible quality standards for investigational products.
Reed will oversee quality assurance at Snapdragon, including at our state-of-the-art GMP drug substance facility opening later this year at 360 Second Avenue in Waltham. “Lisa brings tremendous drug development experience to Snapdragon. Her expertise in pharmaceutical manufacturing and Good Manufacturing Practices (GMP) are an asset to Snapdragon, our clients and our partners as we expand our cGMP manufacturing capability” says Snapdragon CEO Matthew Bio.
“I’m grateful to the Snapdragon team for the opportunity to work with this industry-leading group,” said Reed. “It truly takes a team effort to ensure quality systems stay consistent with cGMP guidelines. I will be building on the solid foundation that the Company has already put in place. I look forward to leading the team’s QA function and I am excited to get started, especially as we move towards Snapdragon’s new lab facility, which will expand clinical manufacturing capabilities.”
Reed comes to Snapdragon from Syndax Pharmaceutical, where she served as senior director of Good Manufacturing Practices (GMP) quality assurance. Prior to joining Syndax, she spent more than six years as the owner and principal consultant of L. Reed Global QA, Inc. Reed has also worked at EISAI, Inc. as global development quality assurance director. Before joining EISAI, Reed held director-level positions at Shire Pharmaceuticals Group, Altarex, Inc. and Reprogenesis/Curis.
Reed earned her BS in Biomedical Laboratory and Clinical Sciences from Boston University and holds a Master of Management degree.
About Snapdragon Chemistry Snapdragon Chemistry specializes in active pharmaceutical ingredient (API) batch and continuous flow process development, utilizing state-of-the-art automation technology and proprietary equipment to solve complex process and analytical development challenges. With R&D and manufacturing headquartered in Waltham, Massachusetts, Snapdragon’s 70+ employees come with strong ties to the local scientific community, with 31 PhD scientists on staff. For more information, please contact info@snapdragonchemistry.com.